The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

Brigatinib, a next‐generation anaplastic lymphoma kinase (ALK) inhibitor, received accelerated approval in the United States for the treatment of patients with metastatic ALK(+) non–small‐cell lung cancer who have progressed on or are intolerant to crizotinib. A clinical study was conducted to asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Tugnait, Meera, Gupta, Neeraj, Hanley, Michael J., Venkatakrishnan, Karthik, Sonnichsen, Daryl, Kerstein, David, Dorer, David J., Narasimhan, Narayana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767012/
https://www.ncbi.nlm.nih.gov/pubmed/30570839
http://dx.doi.org/10.1002/cpdd.641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767012/
https://www.ncbi.nlm.nih.gov/pubmed/30570839
http://dx.doi.org/10.1002/cpdd.641

Ejemplares similares